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based on Brazilian guidelines for HTA (Vianna, 2007). The study was based on clinical 
data published by AWAD 2007, showing PHS device has lower recurrence rate com-
pared to Polypropylene mesh (0.6% versus 2.7%, p  0.04) in 17 months. The recur-
rence rate was projected to 60 months (PHS 2.1%; Polyprolylene mesh 9.2%) to 
evaluate clinical and economic long-term impact. The average incidence rate of 2% 
for inguinal hernia was based on Brazilian specialist’s opinions. The econom impact 
of recurrence was calculated considering 200.000 patients. Procedure costs, hospital 
stay, devices costs and medical staff fees were obtained from Brazilian public lists 
(CBHMP 4a. ed., Boletim Proahsa and SIMPRO). According to local guidelines, 5% 
of discount rate was adopted. One-way sensitivity analysis was performed to verify 
the robustness of the results. RESULTS: According to the model, 108 patients will 
need reintervention in the Polypropylene mesh group versus 24 in the PHS group in 
17 months, representing 74% on reoperation reduction. In 60 months, 368 patients 
will need reintervention in the Polypropylene group versus 84 in the PHS, 77% reop-
eration reduction. There was a positive impact of recurrence in the PHS group of 
R$ 105,401 for a 17 months period (R$ 100,382 discounted) and R$ 355,821 for a 
60 months period (R$ 292,730 discounted). CONCLUSIONS: Findings suggest PHS 
as a safe and efﬁcient alternative for inguinal hernia repair when compared with 
Polypropylene mesh and can generate resource economy under the payer perspective 
in Brazil.
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OBJECTIVES: Opioid induced constipation (OIC) is an important adverse event in 
the management of patients with chronic pain. The aim of this project was to describe 
the current management (prevention, treatment, complications) and resource use of 
OIC in Belgium (B) and The Netherlands (NL), and to estimate to estimate the associ-
ated cost (societal perspective). METHODS: A 2-round Delphi panel was performed 
in a sample both of 24 general practitioners (GPs) (12 per country). Questions were 
related to current medical practice (medical treatment, tests and imaging, consulta-
tions, hospitalizations, treatment of complications and impact of OIC on work pro-
ductivity). Pain was deﬁned as persisting for at least three months and for which 
opioids were permanently administered. Costs were calculated by multiplying average 
resource use obtained from the Delphi panel with speciﬁc unit costs (ofﬁcial tariffs). 
RESULTS: The cost per day for prevention of OIC (before a ﬁrst episode (primary) 
or to prevent a new episode (secondary)) was respectively a1.33 and a2.13 for Belgium 
and The Netherlands. Respectively 68%/89% of the patients in Belgium/The Nether-
lands received primary laxative-prophylaxis (average duration per 3 months: 47 days 
(B) and 58 days (NL)). Secondary prophylaxis was given in 100% of the patients. The 
cost of a constipation-episode was 130a in Belgium, a102 in The Netherlands. The 
higher cost in Belgium was mainly due to higher cost for tests and treatment. Cost of 
complications (B: 8% of patients, NL: 12%) of OIC ranged in Belgium between a71 
(abdominal pain) and a1386 (rectal prolapse). Cost of complications in The Nether-
lands ranged between a23 (vomiting) and a410 (faecal impaction). Work absenteeism 
due to OIC and related complications resulted in a cost of a42 for Belgium and a128 
for The Netherlands. CONCLUSIONS: Management of OIC has an important eco-
nomic impact both in Belgium and The Netherlands, especially when complications 
occur.
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OBJECTIVES: To compare the cost-effectiveness of iv PPI (80 mg bolus followed by 
8 mg/h infusion for 72 h) in patients considered at risk of gastric or duodenal ulcer 
(peptic ulcer) rebleeding after therapeutic endoscopy. METHODS: A systematic 
review and mixed treatment comparison (WinBUGS) provided estimates of the relative 
risk of peptic ulcer rebleed, repeat endoscopy and emergency surgery with acute iv 
PPI using placebo as a common comparator. A decision analytic model was then used 
to determine the cost per quality adjusted life years (QALYs) gained for iv esomepra-
zole, iv pantoprazole and iv omeprazole. Patients with no rebleed received 28-day 
treatment with the respective oral PPI (esomeprazole 40 mg od, pantoprazole 40 mg 
od or omeprazole 20 mg od). Costs of medical and operative procedures were sourced 
from the National Schedule of Reference Costs (2007/08). Disutilities for repeat 
endoscopy and surgery were estimated from a published study that used time trade 
off interviews in adults with peptic ulcer disease. A 30-day time horizon was used. 
The analysis was conducted from the perspective of the UK National Health Service 
(NHS). Uncertainty was investigated through one way sensitivity analysis and proba-
bilistic Monte Carlo simulation. RESULTS: Intravenous esomeprazole was the pre-
ferred treatment strategy. Probabilistic Monte Carlo simulation indicated that, at a 
threshold of £20,000/QALY, there was a 66% probability that iv esomeprazole was 
the most cost-effective compared to 33% and 1% for iv omeprazole or iv pantopra-
zole, respectively. The NHS would need to adopt a cost-effectiveness threshold in 
excess of £65,000/QALY for iv omeprazole to be considered the most cost-effective 
treatment for this indication. CONCLUSIONS: Based on the current best available 
evidence, iv esomeprazole, the only European licensed iv PPI for the prevention of 
recurrent peptic ulcer bleed after therapeutic endoscopy, is the most cost-effective 
treatment option and represents good value for money for the NHS.
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BACKGROUND: Iron deﬁciency and anaemia (Hb-level      12 g/dl) is common in 
patients with inﬂammatory bowel disease (IBD). First line treatment for correcting 
iron deﬁciency is oral iron. In patients intolerant to oral iron, intravenous (IV) iron 
is recommended. OBJECTIVES: To evaluate incremental costs and effects (ICER) of        
IV iron compared to discontinuation of oral iron, in IBD patients intolerant to oral 
iron. METHODS: A micro-simulation model of the Hb-level and intravenous or oral          
iron treatment was developed using published data, a chart review of IBD patients 
and calibration. QALYs and costs for drug (including administration), transport and 
loss of production due to IV iron administration in an outpatient setting were esti-
mated using a one-year time frame with two relapses causing anaemia. At treatment 
start, patients are in relapse with a Hb-level of 10 g/dl and treated with oral iron. As        
they become intolerant, the model either switches them to IV iron or discontinues 
treatment. Sensitivity analyses were carried out with respect to initial Hb and number 
of relapses per year. RESULTS: In the base case, treatment with IV iron generates a 
QALY gain of 0.0334 at a cost of a1,530, i.e. an ICER of a45,800. A treatment start 
at lower initial Hb-levels generates higher QALY-gains and lower costs per QALY, 
e.g. a35,900 per QALY gained with an initial Hb-level of 9 g/dl. The ICER in patients 
with one relapse per year gain is a61,460, reﬂecting a high initial cost when determin-
ing appropriate iron treatment regimen. CONCLUSIONS: In a health care perspective,     
IV iron compared to oral iron is cost-effective in patients in relapse. In a societal 
 perspective, IV iron is cost-effective provided that 50% of the patients work 
during relapse.
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OBJECTIVES: Adherence to the prescribed treatment regimen is an important factor 
that impacts on the success of therapy in chronic hepatitis C. The aim of this study 
was to develop a cost-effectiveness analysis of a multidisciplinary support program 
(MSP) versus conventional treatment in a group of Hepatitis C (HC) patients. 
METHODS: A total of 278 naïve and mono-infected patients with HC were included 
in the study: 131 in Group 1 (MSP strategy) and 147 in Group 2 (conventional treat-
ment approach). All patients were treated with Peg-IFN-alfa-2a and Ribavirin. The 
MSP not only included hepatologists and nurses, but also, pharmacists, psychologists 
and assistants; additionally uniform patient education, open and ﬂexible visits schedul-
ing, continued evaluation of psychiatric risk and active medication were carried out. 
A decision-tree model was built to estimate the incremental cost-effectiveness ratio 
(ICER) of MSP vs. conventional control. Unitary costs of HC drugs and professionals 
were included. Effectiveness was measured in terms of sustained virological response 
(SVR), adherence was deﬁned as 80% dose administered. RESULTS: For genotypes 
1/4 (G-1/4), adherence was achieved in 92.4% of patients in group 1 and 69.3% in 
group 2 (p  0.0005), for genotypes 2/3 (G-2/3) adherence was achieved in 96.9% 
and 93.2% in groups 1 and 2 respectively (p  0.05). SVR differed in the two groups: 
66.7% in group 1 and 48.9% in group 2 for G-1/4 (p  0.03) and 87.7% and 81.4% 
for G-2/3 (p  0.05) for groups 1 and 2 respectively. Cost per SVR was higher in 
group 2 than in group 1 (a24,079 and a20,197 in G-1/4; a8,351 and a7,723 in G-2/3). 
The ICER was a9,533/SVR in G-1/4 patients and group 1 was dominant over group 
2 in G-2/3 patients. CONCLUSIONS: The MSP could improve the adherence to the 
HC treatment and therefore the virological response, and could be also a cost-effective 
strategy compared with the conventional approach.
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OBJECTIVES: To estimate the cost effectiveness of inﬂiximab treatment among         
patients with severely active ulcerative colitis (UC) hospitalised with an acute exacer-
bation. METHODS: A decision analytic model was used to simulate the progression          
of hypothetical cohorts of patients with an exacerbation of UC receiving different 
treatment strategies, inﬂiximab, ciclosporin, standard care or surgical intervention. 
For extrapolation beyond the trial period, a Markov model was used. The relative 
risk of disease progression on different treatment alternatives was determined by an 
indirect comparison between clinical trial. The primary outcome was quality adjusted 
life years (QALYs) using EQ-5D estimates. A time horizon of one year was selected 
based on the decision problem and the availability of evidence. Costs and beneﬁts 
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were discounted at 3.5%. The base case analysis used a conservative estimate of 80 kg  
for the patient. Uncertainty around the cost effectiveness estimates was explored using          
one-way and probabilistic sensitivity analysis. RESULTS: Inﬂiximab verses ciclosporin   
resulted in an ICER of £19,290 while inﬂiximab therapy dominated standard care and 
surgery treatment options. Changing the utility estimates, medium term ciclosporin 
colectomy probability, and long term treatment effect results in the ICER values being 
above the cost effectiveness threshold of £30,000 per QALY. CONCLUSIONS: 
 Inﬂiximab can be considered as a cost effective treatment compared to standard            
care in patients with severely active ulcerative colitis (UC) hospitalised with an acute 
exacerbation in Scotland.
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OBJECTIVES: To estimate resource utilization and direct medical cost of chronic 
hepatitis C (CHC) from a Thai payer perspective. METHODS: Medical records of 
CHC patients diagnosed during 2003–2006 at 5 major tertiary-care hospitals in 
Thailand were retrospectively reviewed. Data on CHC-related resource use were col-
lected from diagnosis date to the end of 2007 or the last follow-up date or death date, 
depending on which date came ﬁrst. Using micro-costing method, resource utilization 
categorized as laboratory tests, outpatient visits (OPD), inpatient admissions (IPD), 
procedures and medications were measured for 6 health states of CHC, i.e. CHC, 
compensated cirrhosis (CC), decompensated cirrhosis (DC), hepatocellular carcinoma 
(HCC), liver transplantation at year 1 (LT1), and subsequent years post-transplantation 
(LT2). Costs were estimated using reference prices published by Ministry of Public 
Health and were valued in year 2008 Thai Baht (35 Baht  1 USD). RESULTS: A 
total of 542 patients were identiﬁed with 1578 person-years of follow-up time. OPD 
rate was highest in HCC (7 visits/patient/year). IPD rates increased by 289% from 
CC to DC and 1377% from CC to HCC. Mean lengths of stay per admission were 
9 days in DC and 6 days in HCC. Usage rates of medications for liver complications 
were also increased in DC and HCC. Average annual treatment costs per patient were: 
CHC 243,292 Baht (US$6,951); CC 251,148 Baht (US$7,176); DC 154,686 Baht 
(US$4,420); HCC 171,975 Baht (US$4,914); LT-1, 608,771 Baht (US$17,393) and 
LT2 100,818 Baht (US$2,881). CONCLUSIONS: Resource utilization rates in 
CHC patients increase as the disease progresses. Although inpatient bed charges are 
relatively low and no doctor fee paid for outpatient visits in public hospitals, consump-
tion of these health care resources could have been avoided. Interventions which 
prevent or delay liver disease progressions will profoundly reduce economic burden 
of CHC.
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OBJECTIVES: Constipation is a frequent and possibly debilitating adverse event of 
analgesic treatment with opioids. A new drug combining the opioid oxycodone and 
the opioid antagonist naloxone provides equivalent analgesia to oxycodone alone with 
signiﬁcant improvement in bowel function, as demonstrated in a 12-week randomized 
controlled trial in moderate/severe non-cancer pain (OXN3001). This analysis assessed 
the cost-utility of oxycodone/naloxone vs. oxycodone in Belgium and The Nether-
lands. METHODS: A decision model was developed in MS Excel™. In this model, 
costs (a, Societal perspective) and effects (QALYs) of both strategies were calculated 
over a 3 (base case) to 12-month horizon (no discounting). The proportion of patients 
experiencing opioid-induced constipation (OIC) was derived from the OXN3001 trial. 
Medical resource use for OIC prevention, treatment and complications was collected 
using a Delphi panel including 24 Belgian and Dutch GPs. National tariffs were 
applied to obtain corresponding costs. Utility scores were derived from the SF-36 
questionnaire collected during the OXN3001 trial. Deterministic and probabilistic 
sensitivity analyses were performed. RESULTS: At 3 months, oxycodone/naloxone 
was dominant over oxycodone in The Netherlands, while the incremental cost-
 effectiveness ratio (ICER) was a16,389a/QALY in Belgium (incremental drug cost: 
The Netherlands a115, Belgium 153a; OIC-related savings The Netherlands 136a, 
Belgium a110; QALYs gained: both countries 0.0026). At 12 months, the ICER was 
a12,786/QALY in The Netherlands and a25,421/QALY in Belgium. The proportion 
of patients experiencing at least 1 OIC episode during a 4-week analgesic treatment 
was the most sensitive parameter. A Monte Carlo analysis showed that, assuming a 
willingness to pay threshold of a20,000/QALY (The Netherlands) and a30,000/QALY 
(Belgium), oxydone/naloxone was cost-effective in 58% (The Netherlands) and 63% 
(Belgium) of the 1000 simulations (3-month horizon). CONCLUSIONS: Analgesia 
with oxycodone/naloxone is cost-effective (Belgium) or even dominant (The Netherlands) 
at three months and remains cost-effective up to one year.
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OBJECTIVES: To estimate the resource use and associated cost of treating opioid-
induced constipation (OIC) episodes in cancer patients in Sweden where laxatives 
within current SPC-text have failed. METHODS: Nurses in 3 hospices and 10 home 
care centers across Sweden with experience in caring for cancer patients on opioid 
therapy were selected to participate in an interview series. An interview protocol was 
developed in consultation with an expert. The nurses reported on the frequency of 
OIC episodes, treatment practices and resource use related to constipation. The cost 
components included personnel costs (based on time spent on constipation-related 
tasks), transportation costs (for home care visits) and resource costs. The cost per hour 
for personnel was based on the average salary levels of applicable medical personnel 
in Sweden and overhead cost. The average cost per constipation episode was estimated 
and used to project direct health care cost of OIC in Sweden. RESULTS: The nurses 
reported that on average 24% of patients in home care and 45% of patients in hospices 
had a constipation episode every second week or more often with laxatives in labeled 
doses. The nurses estimated the length of the constipation episode to be between 2–5 
days. Three steps were identiﬁed in the treatment process—increase in dosage of laxa-
tives (100%), provision of suppositories and enemas (40%) and manual disimpaction 
or bowel investigation/contrast X-ray (3% of cases). Nurses spent on average 3.5 
hours ranging across 2 additional visits for treating each episode of OIC. The average 
cost per episode of OIC was estimated to SEK 1700. Direct health care costs of OIC 
in cancer patients who have failed laxatives within current SPC-text, were estimated 
to SEK 40 million per year in Sweden. CONCLUSIONS: Opioid-induced constipation 
in cancer patients in Sweden is associated with signiﬁcant resource use and costs.
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OBJECTIVES: To assess the extent and main drivers of health care resource consump-
tion in patients admitted with non-variceal upper gastrointestinal bleeding (NVUGIB). 
METHODS: This observational, retrospective cohort study (NCT00797641; 
ENERGiB) was conducted in several European countries (Belgium, Greece, Italy, 
Norway, Portugal, Spain and Turkey). Eligible patients were those consecutively 
admitted to hospital (1 October–30 November 2008) who underwent endoscopy for 
overt NVUGIB (haematemesis, melaena or haematochezia, with other clinical/labora-
tory evidence of acute upper gastrointestinal blood loss). Management of patients 
proceeded according to routine care at each centre. During a 30-day follow-up period, 
data on various clinical outcomes were collected from patient medical records. The 
present analysis reports differences between countries in consumption of health care 
resources. RESULTS: A total of 2661 patients (65% men; mean age 67.7 years) were 
enrolled. The mean number of days of hospitalisation (standard deviation [SD]) was 
8.9 (5.9) days. A wide inter-country variation was observed, ranging from 7.4 (4.9) 
days in Turkey to 10.8 (7.5) days in Belgium. Empirical treatment for NVUGIB was 
administered pre-endoscopy in 68.9% of patients (range 35.1% [Belgium] to 88.7% 
[Turkey]), most frequently proton pump inhibitors (PPIs) (66.0% of patients, ranging 
from 32.8% [Belgium] to 87.7% [Turkey]). Therapeutic procedures were performed 
during endoscopy in 35.8% of patients (range 24.9% [Greece] to 40.6% [Belgium]). 
Most commonly performed related procedures were transfusions (any intravenous 
ﬂuid; 84.6% of patients, range 74.0% [Belgium] to 92.3% [Portugal]) and additional 
endoscopies (28.7%, range 12.6% [Turkey] to 53.6% [Belgium]). Treatment for 
NVUGIB was administered post-endoscopy in 93.2% of patients, most commonly 
PPIs (92.6%); a narrow inter-country range was observed. CONCLUSIONS: Manage-
ment of NVUGIB is associated with substantial consumption of health care resources 
in European countries. There is wide variation across Europe; generally, the highest 
rates of resource utilisation are observed in Belgium and the lowest in Turkey.
GASTROINTESTINAL DISORDERS – Patient-Reported Outcomes Studies
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OBJECTIVES: To assess the effect of subcutaneous Methylnaltrexone on generic 
Health Related Quality of Life using the EQ-5D index scores in patients on opioid 
therapy for chronic non-malignant pain with opioid-induced constipation. METHODS: 
In this study, 469 subjects were randomized to either methylnaltrexone daily (QD), 
every other day (QOD) dosing or placebo for 4 weeks. Eligibility criteria included an 
